Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chemoradiotherapy + panitumumab (Radboud University Medical Center)
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CRT + panitumumab is a combination treatment regimen investigated for the treatment of irresectable esophageal cancer, including both squamous cell carcinoma and adenocarcinoma. This regimen integrates panitumumab (Vectibix), a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR), with standard concurrent chemoradiotherapy (CRT). The chemotherapy component typically involves either a combination of cisplatin and 5-fluorouracil or weekly carboplatin and paclitaxel, administered alongside external beam radiation therapy. By inhibiting EGFR-mediated signaling pathways that promote tumor growth and survival, panitumumab is intended to sensitize cancer cells to the cytotoxic effects of radiation and chemotherapy, potentially improving survival outcomes in patients with locally advanced, inoperable disease.
- Brand names
- Vectibix
- Other names
- CRT + panitumumabConcurrent chemoradiotherapy plus panitumumabVectibix + CRT
02
Targets
Beyond the preview
Go deeper on chemoradiotherapy + panitumumab (Radboud University Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chemoradiotherapy + panitumumab (Radboud University Medical Center).